GlassScriptPhysician profile
Alexandra M Lacey
NPI 1740608462
$11,367.27
in general payments reported to CMS, 2019-2025
9 companies · $6,862 in 2025
The $6,862 reported for 2025 was more than what 93% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2022: $146 · 2023: $256 · 2024: $3,442 · 2025: $6,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,500 · Travel and Lodging: $1,162 · Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,500.00 |
| Travel and Lodging | $1,161.84 |
| Food and Beverage | $898.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $10,066.39 | 2024-2025 | Cohealyx, Recell, Permeaderm |
| Integra Lifesciences Corporation | $711.35 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Access Pro Medical, LLC | $185.75 | 2023 | Matriderm |
| Molnlycke Health Care US, LLC | $119.80 | 2019 | |
| Kci USA, INC. | $82.43 | 2019 | |
| Vericel Corporation | $81.08 | 2022-2025 | Nexobrid, Epicel (Cultured Epidermal Autografts) |
| Polynovo North America LLC | $71.67 | 2023-2025 | Novosorb Btm |
| Smith+Nephew, INC. | $48.80 | 2023-2024 | Acticoat 4" X 4", Oasis, Versajet |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Lacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.